An IP Australia delegate has shot down Apple’s application to patent a touchscreen interface used on its electronic devices, calling the invention a “logistical scheme” for organising media files rather than a technological innovation.
Cargill has won a trade mark infringement case against a company that a judge said appeared to be operating an “internet scam” to intercept a $10 million payment to the multinational food company.
A three-year court battle over PepsiCo’s Monster Munch trade mark has been resolved, with Monster Energy negotiating the removal of some beverage products that would have been covered by the mark.C
The Iconic has defeated a challenge to the online fashion retailer’s application to trade mark ‘Considered’ for sustainable or ethically sourced products, with IP Australia rejecting Net-a-Porter’s argument that the label has not been used in the sense required under the Trade Marks Act.
The High Court has declined to step in after Hells Angels’ award of $78,000 in damages for online marketplace Redbubble’s infringement of its trade marks was slashed to just $100, bringing to an end an IP fight that has stretched on for nearly a decade.
Fortescue has brought legal action against start-up Element Zero and three former employees, alleging “industrial scale misuse” of the Western Australian mining company’s confidential information.
Drug giant Pfizer has blasted Samsung Bioepis’ “fishing expedition” in its suit alleging infringement of the patent for its blockbuster arthritis drug Enbrel, telling the court the Korean biotech should not be allowed to dig for new grounds of invalidity.
A judge has upheld Neurim Pharmaceutical’s claim for additional damages against two generic drug companies found to have infringed its patent for insomnia drug Circadin, despite the company’s failure to comply with an earlier ruling.
Otsuka Pharmaceutical has hit back at suit filed by Indian generics company Sun Pharma seeking to invalidate its patent for blockbuster antipsychotic Abilify, filing a cross-claim seeking to restrain Sun Pharma from infringing the patent with a generic version of the drug.
Drug giant Glaxo has succeeded in extending the term for a patent for a drug that treats chronic obstructive pulmonary disease and asthma, with a delegate rejecting arguments from law firm Banki Haddock Fiora that the application was incorrectly based on a patent that was no longer valid because of amendments.